Inogen Inc

Inogen is well-positioned for growth due to strong demand for portable oxygen concentrators, new product launches, and international expansion, though U.S. channel shifts and reimbursement risks remain. The company's shares have declined 16.7% year-to-date, underperforming the S&P 500's 11.2% gain, and it carries a Zacks Rank #3 (Hold). Second-quarter 2026 POC unit volumes rose more than 12% year over year, international revenues increased 15% to $41.3 million, and new products Voxi and Aurora contributed over 100 basis points to growth. However, U.S. sales fell 2% and rental revenues dropped 12% as the shift toward home medical equipment providers pressures direct-to-consumer and rental channels. The Zacks Consensus Estimate for 2026 revenues is $356.7 million, implying 2.3% growth, and the loss per share estimate has narrowed by 3 cents to 74 cents over the past 60 days.

Inogen is well-positioned for growth driven by the expanding portable oxygen concentrator market and international expansion, though U.S. revenue pressure from channel shifts remains a key risk. The company estimates that approximately 60% of new long-term oxygen therapy patients now begin treatment with a portable oxygen concentrator, up from less than 40% a few years ago, supporting strong business-to-business demand. International revenues increased 18% year over year in the first quarter of 2026, helped by expansion in Eastern Europe, Latin America, and Asia-Pacific, while U.S. sales declined 5% and rental revenues fell 8% in the same period. Inogen is also broadening its product portfolio with launches such as the Aurora CPAP mask family and the Simeox airway clearance technology, creating cross-selling opportunities. The Zacks Consensus Estimate projects a loss per share of 77 cents for 2026 on revenues of 369.3 million dollars, representing 5.9% revenue growth from the prior year.